Core Viewpoint - China Medical System Holdings Limited (CMS) has received approval from the National Medical Products Administration (NMPA) for its new drug Desidustat Tablets, aimed at treating renal anaemia in non-dialysis adult Chronic Kidney Disease (CKD) patients [1][2]. Group 1: Product Approval and Market Impact - The approval of Desidustat Tablets enhances CMS's positioning in the nephrology sector and complements its existing product, Velphoro, which treats CKD hyperphosphatemia [2]. - CMS anticipates rapid clinical application of Desidustat Tablets through effective resource linkage and channel networks, aiming to provide differentiated treatment options for CKD patients in China [2]. Group 2: Clinical Efficacy and Unmet Needs - Desidustat Tablets function as a novel oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), promoting erythropoiesis by increasing endogenous erythropoietin and improving iron availability [3]. - Clinical trials in China have shown that Desidustat significantly increases haemoglobin levels compared to placebo, with long-term studies indicating it can maintain target haemoglobin levels safely [3]. - There is a significant unmet need for effective anaemia treatments in CKD patients, with over 120 million CKD patients in China and low treatment compliance rates among non-dialysis patients [4]. Group 3: Strategic Focus and Innovation - CMS follows an "innovation-driven" strategy, with a diverse product portfolio that includes 7 approved drugs and nearly 20 projects in clinical trials [6]. - The company aims to enhance its innovative pipeline with first-in-class and best-in-class products, focusing on clinical needs to deliver quality pharmaceutical solutions [6][8]. - CMS is committed to expanding its operations in specialty therapeutic fields, including cardiovascular, kidney, metabolic, gastroenterology, ophthalmology, and skin health, to strengthen its market position [9].

Core Viewpoint - China Medical System Holdings Limited (CMS) reported positive interim results for the first half of 2025, indicating successful strategic transformation with year-on-year growth in both revenue and profit [1][2][3] Financial Performance - Revenue for the six months ended June 30, 2025, was approximately RMB4.00 billion, a year-on-year increase of 10.8% [1] - If all medicines were directly sold by the company, revenue would be approximately RMB4.67 billion, reflecting an 8.9% year-on-year growth [1] - Net profit was approximately RMB0.93 billion, representing a 3.1% year-on-year increase [1] Strategic Transformation - CMS has emerged from the impact of National Volume-based Procurement (National VBP), with expectations for sustainable growth [2] - Revenue from key non-National VBP exclusive/branded products and innovative products reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue [2] - The company’s strategic upgrade has been confirmed through solid operating results and innovation outcomes [3] Innovation and Product Development - The "product innovation" strategy is a key growth engine, utilizing overseas licensing, domestic collaboration, and in-house R&D [4] - CMS has successfully commercialized five innovative drugs in China, with additional products expected to receive marketing approvals by 2025 [5] - The innovative pipeline includes several blockbuster candidates in late-stage clinical development, expected to be commercialized within the next one to three years [6] Market Expansion and Commercial Model Reform - CMS is advancing its "New Models" strategy, focusing on specialty therapeutic fields and expanding into new retail and media channels [10][11] - The company completed a secondary listing on the Main Board of the Singapore Exchange, marking a milestone in its internationalization strategy [12] - The skin health business, Dermavon, has shown strong potential and is proposed to be spun off for separate listing to unlock its value [11] Future Outlook - The growth logic of "New CMS" is expected to accelerate, improving profitability and performance resilience [13] - The company aims to deliver quality pharmaceutical products and services globally, generating sustainable returns for shareholders [13]